‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.
Putnam Allstate Advisor Plus
Putnam Global Health Care Subaccount
The subaccount seeks capital appreciation.
Fund description
The subaccount seeks to capitalize on the strength of the health-care sector, targeting companies of all sizes. Holdings encompass an array of industries, including pharmaceuticals, health-care services, and biotechnology. The fund seeks companies that offer strong long-term growth prospects, regardless of their size.
Sales story
Investing in the health-care sectorA dynamic sectorFrom biotech and drugs to devices and hospitals, the fund invests in industries that can profit from the global demand for health-care products and services.Seeks growth from innovationInnovative health-care solutions are always in demand, giving the fund potential for positive returns regardless of economic conditions.Active managementSupported by experienced research analysts, the portfolio manager uses bottom-up research to assess scientific innovation, regulatory changes, and company fundamentals.
Management team
- Michael J. Maguire, CFA (Investing since 2002)
Daily pricing as of 10/22/21
| with optional enhanced death benefits | ||
|---|---|---|
| Unit Value | $35.609133 | $34.45533 |
| Unit Value Change | 0.118468 | 0.114488 |
Quick facts as of 09/30/21
| Fiscal Year End | December |
| Asset Class | Putnam Allstate Advisor Plus |
| Subaccount Status | Open to new investors |
| Number of issues | 51 |
| Turnover (fiscal year end) | 82% |
| Net Assets | $166M |
| Inception Date | 04/30/98 |
Performance
Performance as of 09/30/21
| Annualized Performance | Last Quarter | Year to Date |
1 yr. | 3 yrs. | 5 yrs. | 10 yrs. | Life of subaccount |
|---|---|---|---|---|---|---|---|
| Restated performance | |||||||
| Unit Value | 2.01% | 9.19% | 17.89% | 12.61% | 10.78% | 13.99% | 6.13% |
| Standardized | -5.99% | 1.19% | 9.89% | 10.47% | 9.97% | 13.99% | 6.13% |
| With optional enhanced death benefit | |||||||
| Unit Value | 1.98% | 9.06% | 17.72% | 12.45% | 10.61% | 13.82% | 5.96% |
| Standardized | -6.02% | 1.06% | 9.72% | 10.30% | 9.80% | 13.82% | 5.96% |
| Actual performance | |||||||
| Unit Value | 2.01% | 9.19% | 17.89% | 12.61% | 10.78% | 13.99% | 5.68% |
| Standardized | -5.99% | 1.19% | 9.89% | 10.47% | 9.97% | 13.99% | 5.68% |
| With optional enhanced death benefit | |||||||
| Unit Value | 1.98% | 9.06% | 17.72% | 12.45% | 10.61% | 13.82% | 5.52% |
| Standardized | -6.02% | 1.06% | 9.72% | 10.30% | 9.80% | 13.82% | 5.52% |
Annual Performance at NAV
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|
| -2.76% | 20.31% | 39.40% | 25.60% | 6.06% | -12.77% | 13.46% | -2.19% | 28.21% | 14.42% |
| With optional enhanced death benefit | |||||||||
| -2.90% | 20.12% | 39.19% | 25.41% | 5.90% | -12.90% | 13.29% | -2.34% | 28.02% | 14.25% |
Restated performance
Monthly as of 09/30/21 |
|
|---|---|
| Unit Value | -3.86% |
| Standardized | -11.55% |
YTD as of 10/22/21 |
|
|---|---|
| Unit Value | 12.36% |
| Standardized | 4.36% |
With optional enhanced death benefit
Monthly as of 09/30/21 |
|
|---|---|
| Unit Value | -3.87% |
| Standardized | -11.56% |
YTD as of 10/22/21 |
|
|---|---|
| Unit Value | 12.23% |
| Standardized | 4.23% |
Unit values and performance information shown apply to the specific annuity product listed, not the underlying Putnam Variable Trust fund. This information should not be used by investors who hold an interest in Putnam Variable Trust funds through a different annuity or other variable product. The unit values and performance of other variable products that offer Putnam Variable Trust funds may be higher or lower due to product charges and expenses or other factors.
Data is historical. Past performance is no guarantee of future results. More recent returns may be less or more than those shown. Investment return and principal value will fluctuate, and you may have a gain or a loss when you sell your units.
Returns shown for the subaccounts for periods before their inception are derived from the historical performance of the underlying fund, adjusted to reflect the mortality, expense risk, and surrender charges applicable to this product and do not factor in the annual $30 contract maintenance fee. Additional riders and options for insurance-related charges will increase expenses and lower returns. Please see the prospectus for details. For a portion of the period, subaccounts may have limited expenses, without which returns would have been lower.
Variable annuities are long-term investments designed for retirement purposes. Putnam Capital Manager products are flexible-premium variable annuities held by Talcott Resolution Life, Inc., Simsbury, CT.
Putnam Allstate variable annuities are flexible-premium deferred variable annuities issued by Allstate Life Insurance Company (Allstate Life); underwritten by Allstate Distributors, L.L.C., both of Northbrook, IL; and sold through registered representatives or bank employees who are licensed insurance agents. Please check for availability in your specific state.
These policies have limitations and are sold by prospectus only. The prospectus contains details on the variable annuity, the subaccounts, contract features, fees, expenses, and other pertinent information.
Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund before investing. For a prospectus containing this and other information for any variable annuity or variable life product that invests in Putnam Variable Trust funds, contact your financial advisor for a contract prospectus and prospectus for the underlying funds. You may also call Talcott Resolution at 1-800-521-0538 or Allstate at 1-800-390-1277. Read the prospectuses carefully before investing.
For the most recent month-end performance, please call Talcott Resolution at 1-800-521-0538 or Allstate at 1-800-390-1277.
Risk Characteristics as of 09/30/21
| Alpha (%) | 2.72 |
| Beta | 0.97 |
| R Squared | 0.95 |
| Standard Deviation (3 yrs.) | 15.10 |
Holdings
| UnitedHealth Group | 7.32% |
| Astrazeneca | 6.18% |
| Johnson & Johnson | 5.08% |
| Danaher Corp | 4.66% |
| AbbVie | 4.49% |
| Thermo Fisher Scientific | 4.41% |
| Ironwood Pharmaceuticals | 3.69% |
| Abbott Laboratories | 3.38% |
| Ascendis Pharma A/S | 3.17% |
| Innoviva | 3.04% |
| Top 10 holdings, total: | 45.42% |
| Top 10 holdings as of 09/30/21 | |
|---|---|
| 1: UnitedHealth Group | 7.32% |
| 2: Astrazeneca | 6.18% |
| 3: Johnson & Johnson | 5.08% |
| 4: Danaher Corp | 4.66% |
| 5: AbbVie | 4.49% |
| 6: Thermo Fisher Scientific | 4.41% |
| 7: Ironwood Pharmaceuticals | 3.69% |
| 8: Abbott Laboratories | 3.38% |
| 9: Ascendis Pharma A/S | 3.17% |
| 10: Innoviva | 3.04% |
| Holdings represent 45.42% of portfolio | |
| Top 10 holdings as of 08/31/21 | |
|---|---|
| 1: UnitedHealth Group | 6.76% |
| 2: Astrazeneca | 5.72% |
| 3: Johnson & Johnson | 5.19% |
| 4: AbbVie | 4.79% |
| 5: Danaher Corp | 4.72% |
| 6: Thermo Fisher Scientific | 4.07% |
| 7: Ironwood Pharmaceuticals | 3.73% |
| 8: Sanofi | 2.98% |
| 9: Roche Holding Ag | 2.95% |
| 10: Abbott Laboratories | 2.94% |
| Holdings represent 43.85% of portfolio | |
| Top 10 holdings as of 07/31/21 | |
|---|---|
| 1: UnitedHealth Group | 6.94% |
| 2: Astrazeneca | 5.82% |
| 3: Johnson & Johnson | 5.35% |
| 4: AbbVie | 4.78% |
| 5: Danaher Corp | 4.50% |
| 6: Thermo Fisher Scientific | 4.11% |
| 7: Ironwood Pharmaceuticals | 3.76% |
| 8: Eli Lilly | 3.17% |
| 9: Sanofi | 3.08% |
| 10: Roche Holding Ag | 2.94% |
| Holdings represent 44.45% of portfolio | |
| Top 10 holdings as of 06/30/21 | |
|---|---|
| 1: UnitedHealth Group | 6.85% |
| 2: Astrazeneca | 5.83% |
| 3: Johnson & Johnson | 5.20% |
| 4: Abbvie | 4.70% |
| 5: Danaher Corp | 4.12% |
| 6: Eli Lilly | 4.06% |
| 7: Thermo Fisher Scientific | 3.90% |
| 8: Sanofi | 3.18% |
| 9: Ironwood Pharmaceuticals | 3.08% |
| 10: Roche Holding Ag | 2.91% |
| Holdings represent 43.83% of portfolio | |
| UNITEDHEALTH GROUP INC SEDOL 2917766 | 7.32% | ASTRAZENECA PLC SEDOL 0989529 | 6.18% | JOHNSON & JOHNSON SEDOL 2475833 | 5.08% | DANAHER CORP SEDOL 2250870 | 4.66% | ABBVIE INC SEDOL B92SR70 | 4.49% | THERMO FISHER SCIENTIFIC INC SEDOL 2886907 | 4.41% | IRONWOOD PHARMACEUTICALS INC SEDOL B3MZ6K5 | 3.69% | ABBOTT LABORATORIES SEDOL 2002305 | 3.38% | ASCENDIS PHARMA A/S - ADR SEDOL BV9G6B8 | 3.16% | INNOVIVA INC SEDOL BDDXF67 | 3.04% | SANOFI SEDOL 5671735 | 2.91% | ROCHE HOLDING AG-GENUSSCHEIN SEDOL 7110388 | 2.81% | PFIZER INC SEDOL 2684703 | 2.77% | ANTHEM INC SEDOL BSPHGL4 | 2.61% | ELI LILLY & CO SEDOL 2516152 | 2.55% | EDWARDS LIFESCIENCES CORP SEDOL 2567116 | 2.47% | ICON PLC SEDOL B94G471 | 2.40% | MERCK & CO. INC. SEDOL 2778844 | 2.32% | NOVARTIS AG-REG SEDOL 7103065 | 1.64% | LONZA GROUP AG-REG SEDOL 7333378 | 1.54% | BOSTON SCIENTIFIC CORP SEDOL 2113434 | 1.48% | BIO-RAD LABORATORIES-A SEDOL 2098508 | 1.48% | REGENERON PHARMACEUTICALS SEDOL 2730190 | 1.44% | MCKESSON CORP SEDOL 2378534 | 1.43% | HCA HEALTHCARE INC SEDOL B4MGBG6 | 1.39% | MEDTRONIC PLC SEDOL BTN1Y11 | 1.32% | DEXCOM INC SEDOL B0796X4 | 1.25% | NOVO NORDISK A/S-B SEDOL BHC8X90 | 1.16% | 4FRONT VENTURES CORP SEDOL BKFGXD6 | 1.15% | INTUITIVE SURGICAL INC SEDOL 2871301 | 1.08% | GLAXOSMITHKLINE PLC SEDOL 0925288 | 1.08% | MERCK KGAA SEDOL 4741844 | 1.08% | SARISSA CAPITAL ACQUISITION SEDOL BMF7JF7 | 1.05% | ACCELERON PHARMA INC SEDOL BDGTXQ8 | 0.98% | TERRASCEND CORP SEDOL BDFDQ73 | 0.94% | UNITED THERAPEUTICS CORP SEDOL 2430412 | 0.92% | AMERISOURCEBERGEN CORP | 0.82% | MODERNA INC SEDOL BGSXTS3 | 0.79% | TAKEDA PHARMACEUTICAL CO LTD SEDOL 6870445 | 0.76% | ALKERMES PLC SEDOL B3P6D26 | 0.72% | HUMANA INC SEDOL 2445063 | 0.70% | DAIICHI SANKYO CO LTD SEDOL B0J7D91 | 0.63% | BIOGEN INC SEDOL 2455965 | 0.57% | CIGNA CORP SEDOL BHJ0775 | 0.54% | INMODE LTD SEDOL BK5Z9R9 | 0.54% | ASTELLAS PHARMA INC SEDOL 6985383 | 0.48% | TURNING POINT THERAPEUTICS I SEDOL BJXBP30 | 0.42% | TERUMO CORP SEDOL 6885074 | 0.41% | HEALTH SCIENCES ACQUISITIONS SEDOL BMWWF91 | 0.41% | CHUGAI PHARMACEUTICAL CO LTD SEDOL 6196408 | 0.36% | EISAI CO LTD SEDOL 6307200 | 0.27% | GREEN THUMB INDUSTRIES INC SEDOL BFFY829 | 0.21% | TREASURY BILL 00.0000 02/03/2022 | 0.12% | EUR/USD 12/15/2021 HSBCB | 0.06% | GBP/USD 12/15/2021 WPAC | 0.06% | TREASURY BILL 00.0000 02/24/2022 | 0.06% | EUR/USD 12/15/2021 MSCIL | 0.04% | GBP/USD 12/15/2021 SSBT | 0.03% | GBP/USD 12/15/2021 CSI-FX | 0.03% | DKK/USD 12/15/2021 CITI | 0.03% | EUR/USD 12/15/2021 GSFX | 0.02% | GBP/USD 12/15/2021 BCAP-FX | 0.01% | JPY/USD 11/17/2021 BANKAM | 0.01% | JPY/USD 11/17/2021 JPMCB | 0.01% | EUR/USD 12/15/2021 CITI | 0.01% | GBP/USD 12/15/2021 BANKAM | 0.01% | CAD/USD 10/20/2021 HSBCB | 0.00% | CAD/USD 10/20/2021 SSBT | 0.00% | CHF/USD 12/15/2021 UBS | 0.00% | CAD/USD 10/20/2021 GSFX | 0.00% | EUR/USD 12/15/2021 SSBT | 0.00% | NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT | 0.00% | NZD/USD 10/20/2021 JPMCB | -0.00% | ILS/USD 10/20/2021 SSBT | -0.00% | JPY/USD 11/17/2021 BCAP-FX | -0.00% | EUR/USD 12/15/2021 WPAC | -0.00% | CAD/USD 10/20/2021 UBS | -0.00% | JPY/USD 11/17/2021 CSI-FX | -0.00% | EUR/USD 12/15/2021 TDBK | -0.01% | EUR/USD 12/15/2021 UBS | -0.01% | JPY/USD 11/17/2021 SSBT | -0.01% | CHF/USD 12/15/2021 BANKAM | -0.01% | AUD/USD 10/20/2021 BANKAM | -0.01% | JPY/USD 11/17/2021 UBS | -0.01% | EUR/USD 12/15/2021 BCAP-FX | -0.01% | GBP/USD 12/15/2021 HSBCB | -0.01% | JPY/USD 11/17/2021 GSFX | -0.02% | EUR/USD 12/15/2021 RBSF | -0.02% | GBP/USD 12/15/2021 GSFX | -0.02% | GBP/USD 12/15/2021 MSCIL | -0.03% | CHF/USD 12/15/2021 HSBCB | -0.04% | AUD/USD 10/20/2021 RBSF | -0.05% | EUR/USD 12/15/2021 BANKAM | -0.07% |
| UNITEDHEALTH GROUP INC SEDOL 2917766 | 6.85% | ASTRAZENECA PLC SEDOL 0989529 | 5.82% | JOHNSON & JOHNSON SEDOL 2475833 | 5.20% | ABBVIE INC SEDOL B92SR70 | 4.70% | DANAHER CORP SEDOL 2250870 | 4.12% | ELI LILLY & CO SEDOL 2516152 | 4.06% | THERMO FISHER SCIENTIFIC INC SEDOL 2886907 | 3.90% | SANOFI SEDOL 5671735 | 3.18% | IRONWOOD PHARMACEUTICALS INC SEDOL B3MZ6K5 | 3.08% | ROCHE HOLDING AG-GENUSSCHEIN SEDOL 7110388 | 2.91% | ABBOTT LABORATORIES SEDOL 2002305 | 2.84% | ANTHEM INC SEDOL BSPHGL4 | 2.68% | PFIZER INC SEDOL 2684703 | 2.52% | INNOVIVA INC SEDOL BDDXF67 | 2.46% | MERCK & CO. INC. SEDOL 2778844 | 2.41% | ASCENDIS PHARMA A/S - ADR SEDOL BV9G6B8 | 2.38% | MEDTRONIC PLC SEDOL BTN1Y11 | 2.32% | EDWARDS LIFESCIENCES CORP SEDOL 2567116 | 2.10% | BIOGEN INC SEDOL 2455965 | 2.08% | ICON PLC SEDOL B94G471 | 1.90% | NOVARTIS AG-REG SEDOL 7103065 | 1.82% | BRISTOL-MYERS SQUIBB CO SEDOL 2126335 | 1.65% | LONZA GROUP AG-REG SEDOL 7333378 | 1.46% | MCKESSON CORP SEDOL 2378534 | 1.38% | REGENERON PHARMACEUTICALS SEDOL 2730190 | 1.33% | BIO-RAD LABORATORIES-A SEDOL 2098508 | 1.28% | GLAXOSMITHKLINE PLC SEDOL 0925288 | 1.12% | SARISSA CAPITAL ACQUISITION SEDOL BMF7JF7 | 1.08% | NOVO NORDISK A/S-B SEDOL BHC8X90 | 1.02% | ACCELERON PHARMA INC SEDOL BDGTXQ8 | 1.01% | INTUITIVE SURGICAL INC SEDOL 2871301 | 1.00% | NOVAVAX INC SEDOL BJDQXG4 | 0.98% | MERCK KGAA SEDOL 4741844 | 0.95% | UNITED THERAPEUTICS CORP SEDOL 2430412 | 0.90% | 4FRONT VENTURES CORP SEDOL BKFGXD6 | 0.84% | HUMANA INC SEDOL 2445063 | 0.80% | AMERISOURCEBERGEN CORP | 0.79% | TAKEDA PHARMACEUTICAL CO LTD SEDOL 6870445 | 0.76% | GILEAD SCIENCES INC SEDOL 2369174 | 0.68% | CIGNA CORP SEDOL BHJ0775 | 0.64% | TERRASCEND CORP SEDOL BDFDQ73 | 0.63% | ALKERMES PLC SEDOL B3P6D26 | 0.58% | MIRATI THERAPEUTICS INC SEDOL BBPK0J0 | 0.52% | DAIICHI SANKYO CO LTD SEDOL B0J7D91 | 0.51% | ASTELLAS PHARMA INC SEDOL 6985383 | 0.50% | INMODE LTD SEDOL BK5Z9R9 | 0.50% | TURNING POINT THERAPEUTICS I SEDOL BJXBP30 | 0.49% | ROCKET PHARMACEUTICALS INC SEDOL BDFKQ07 | 0.47% | ZIMMER BIOMET HOLDINGS INC SEDOL 2783815 | 0.46% | HEALTH SCIENCES ACQUISITIONS SEDOL BMWWF91 | 0.42% | CHUGAI PHARMACEUTICAL CO LTD SEDOL 6196408 | 0.38% | LABORATORY CRP OF AMER HLDGS SEDOL 2586122 | 0.37% | TERUMO CORP SEDOL 6885074 | 0.36% | EISAI CO LTD SEDOL 6307200 | 0.35% | VOR BIOPHARMA INC SEDOL BLCD876 | 0.29% | GREEN THUMB INDUSTRIES INC SEDOL BFFY829 | 0.25% | TG THERAPEUTICS INC SEDOL B828K63 | 0.23% | SYNDAX PHARMACEUTICALS INC SEDOL BN7Q7R7 | 0.20% | TRULIEVE CANNABIS CORP SEDOL BGNKTH8 | 0.19% | VINCERX PHARMA INC SEDOL BNGJR22 | 0.16% | EUR/USD 09/15/2021 HSBCB | 0.07% | CASH MGMT BILL 00.0000 09/07/2021 | 0.06% | GBP/USD 09/15/2021 WPAC | 0.05% | EUR/USD 09/15/2021 MSCIL | 0.05% | COLUMBIA CARE INC SEDOL BJYS701 | 0.04% | GBP/USD 09/15/2021 SSBT | 0.03% | EUR/USD 09/15/2021 GSFX | 0.03% | GBP/USD 09/15/2021 CSI-FX | 0.02% | DKK/USD 09/15/2021 BANKAM | 0.02% | JPY/USD 08/18/2021 BANKAM | 0.02% | JPY/USD 08/18/2021 JPMCB | 0.02% | GBP/USD 09/15/2021 BANKAM | 0.01% | EUR/USD 09/15/2021 CITI | 0.01% | GBP/USD 09/15/2021 BCAP-FX | 0.01% | CAD/USD 07/21/2021 HSBCB | 0.00% | EUR/USD 09/15/2021 SSBT | 0.00% | NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT | 0.00% | AUD/USD 07/21/2021 BANKAM | -0.00% | JPY/USD 08/18/2021 SSBT | -0.00% | NZD/USD 07/21/2021 JPMCB | -0.00% | CHF/USD 09/15/2021 BANKAM | -0.00% | ILS/USD 07/21/2021 SSBT | -0.00% | JPY/USD 08/18/2021 BCAP-FX | -0.00% | EUR/USD 09/15/2021 WPAC | -0.00% | CAD/USD 07/21/2021 SSBT | -0.00% | EUR/USD 09/15/2021 TDBK | -0.01% | JPY/USD 08/18/2021 UBS | -0.01% | GBP/USD 09/15/2021 HSBCB | -0.01% | JPY/USD 08/18/2021 CSI-FX | -0.01% | EUR/USD 09/15/2021 BCAP-FX | -0.01% | EUR/USD 09/15/2021 UBS | -0.01% | DKK/USD 09/15/2021 CITI | -0.02% | GBP/USD 09/15/2021 GSFX | -0.02% | GBP/USD 09/15/2021 MSCIL | -0.02% | AUD/USD 07/21/2021 RBSF | -0.03% | EUR/USD 09/15/2021 RBSF | -0.03% | JPY/USD 08/18/2021 GSFX | -0.04% | CHF/USD 09/15/2021 HSBCB | -0.06% | EUR/USD 09/15/2021 BANKAM | -0.09% |
Portfolio Composition as of 09/30/21
| Common stock | 97.31% |
| Cash and net other assets | 2.69% |
Consider these risks before investing: International investing involves currency, economic, and political risks. Emerging-market securities carry illiquidity and volatility risks. Investments in small and/or midsize companies increase the risk of greater price fluctuations. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices, or procedures, and changes in governmental and private payment systems. The fund concentrates on a limited group of industries and is non-diversified. Because the fund may invest in fewer issuers than a diversified fund, it is vulnerable to common economic forces and may result in greater losses and volatility. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The use of short selling may result in losses if the securities appreciate in value. Risks associated with derivatives include increased investment exposure (which may be considered leverage) and, in the case of over-the-counter instruments, the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. The value of investments in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund’s other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Top Industry Sectors as of 09/30/21
| Pharmaceuticals | 37.40% |
|---|---|
| Biotechnology | 17.19% |
| Health Care Equipment & Supplies | 16.60% |
| Health Care Providers & Services | 14.82% |
| Life Sciences Tools & Services | 9.84% |
| Cash and net other assets | 2.69% |
| Diversified Financial Services | 1.46% |
0
Country Allocation as of 09/30/21
| United States | 68.97% |
|---|---|
| United Kingdom | 7.26% |
| Switzerland | 5.99% |
| Denmark | 4.33% |
| France | 2.91% |
| Japan | 2.90% |
| Cash and net other assets | 2.69% |
| Ireland | 2.40% |
| Germany | 1.07% |
| Other | 1.48% |
0
Expenses
Sales Charges/Fees
| Breakpoint | Sales Charge | Dealer Allowance | CDSC Liab |
|---|---|---|---|
| $0 - $0 | 0.00% | 0.00% | N |
CDSC
| Year | Percent |
|---|---|
| 1 | 8.00% |
| 2 | 8.00% |
| 3 | 8.00% |
| 4 | 7.00% |
| 5 | 6.00% |
| 6 | 5.00% |
| 7 | 4.00% |
| 8 | 3.00% |
| 9+ | 0.00% |